These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 15416228)
1. STATISTICIAN'S view of Australia's drug and chemical industry. Manuf Chem Aerosol News; 1950 Apr; 21(4):154. PubMed ID: 15416228 [No Abstract] [Full Text] [Related]
2. A perspective on Australia's National Medicines Policy. Tett SE Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524 [TBL] [Abstract][Full Text] [Related]
3. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia. Doran E; Alexander Henry D J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023 [TBL] [Abstract][Full Text] [Related]
4. Lilly's challenge to Australia's drug rationing scheme fails. Burton B BMJ; 2007 Mar; 334(7593):552. PubMed ID: 17363797 [No Abstract] [Full Text] [Related]
5. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies. Hamilton C; Lokuge B; Denniss R Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919 [No Abstract] [Full Text] [Related]
6. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia. Morgan S; McMahon M; Greyson D Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927 [TBL] [Abstract][Full Text] [Related]
7. Why pharmaceutical scientists need to keep an eye on Bowman v. Monsanto. Trippe AJ Pharm Pat Anal; 2013 Jan; 2(1):5-7. PubMed ID: 24236963 [No Abstract] [Full Text] [Related]
8. Australia's agar industry. MAKAROFF A Food Ind; 1946 Oct; 18(10):1545-7. PubMed ID: 20998112 [No Abstract] [Full Text] [Related]
9. Chemistry's small world. Caruana C; Smaglik P Nature; 2005 Aug; 436(7054):1202-3. PubMed ID: 16144050 [No Abstract] [Full Text] [Related]
10. An industry statistician's perspective on PHC drug development. Fridlyand J; Yeh RF; Mackey H; Bengtsson T; Delmar P; Spaniolo G; Lieberman G Contemp Clin Trials; 2013 Nov; 36(2):624-35. PubMed ID: 23648396 [TBL] [Abstract][Full Text] [Related]
11. "Design of phase I and II clinical trials in cancer: a statistician's view.". Decoster G; Cavalli F Cancer Invest; 1987; 5(6):649-50. PubMed ID: 3442736 [No Abstract] [Full Text] [Related]
12. Significant developments in occupational health and safety in Australia's construction industry. Fraser L Int J Occup Environ Health; 2007; 13(1):12-20. PubMed ID: 17427343 [TBL] [Abstract][Full Text] [Related]
13. [Public health and chemical-pharmaceutical companies]. Ribeiro MA Hist Cienc Saude Manguinhos; 2000 Nov-2001 Feb; 7(3):607-26. PubMed ID: 16683337 [TBL] [Abstract][Full Text] [Related]
15. Innovation and stem cell excellence power - Australia's drug potential. Livesey S; Watkinson N Expert Opin Drug Discov; 2008 Mar; 3(3):285-8. PubMed ID: 23480263 [TBL] [Abstract][Full Text] [Related]
16. Should tobacco and alcohol companies be allowed to influence Australia's National Drug Strategy? Freeman B; MacKenzie R; Daube M Public Health Res Pract; 2017 Apr; 27(2):. PubMed ID: 28474051 [TBL] [Abstract][Full Text] [Related]
17. [Development of innovations in industry]. BURICH PT Med Prom SSSR; 1952; 3():25-7. PubMed ID: 14940455 [No Abstract] [Full Text] [Related]
18. Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines. Wang N; Lipworth WL; Ritchie JE; Williams KM; Day RO Intern Med J; 2011 Apr; 41(4):314-20. PubMed ID: 20403068 [TBL] [Abstract][Full Text] [Related]
19. [PLASTICS IN MEDICAL INDUSTRY]. PEREPELKIN VP Med Prom SSSR; 1964 May; 18():7-10. PubMed ID: 14224127 [No Abstract] [Full Text] [Related]
20. [PERSPECTIVES OF THE DEVELOPMENT OF MEDICAL INDUSTRY IN THE UKRAINIAN SSR]. TANCHENKO IM Med Prom SSSR; 1964 Aug; 18():3-7. PubMed ID: 14255295 [No Abstract] [Full Text] [Related] [Next] [New Search]